Cost-effectiveness of Osimertinib in the First-Line...

  • Main
  • 2018 / 05
  • Cost-effectiveness of Osimertinib in the First-Line...
JAMA Oncology 2018 / 05

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR -Mutated Advanced Non–Small Cell Lung Cancer

Aguiar, Pedro N., Haaland, Benjamin, Park, Wungki, San Tan, Pui, del Giglio, Auro, de Lima Lopes, Gilberto
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
JAMA Oncology
DOI:
10.1001/jamaoncol.2018.1395
Date:
May, 2018
File:
PDF, 139 KB
english, 2018
Conversion to is in progress
Conversion to is failed